ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
Long-term evaluable patients demonstrate ongoing complete response of 7 and 15 months after receiving a total of eight doses four cycles of CD19 CAR-NK plus rituximab, with no further treatment thereafter The first chemotherapy free, lymphodepletion-free CAR- NK cell therapy demonstrating 100% disease control in first four subjects, all administered as outpatient therapy QUILT-106 off-the-shelf CD19 CAR-NK trial is ongoing and represents a next-generation NK cell therapy for Non-Hodgkins Lymphoma CULVER CITY, Calif., January 16, 2026 BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced updated efficacy and safety results from the ongoing QUILT-106 clinical study (NCT06334991) evaluating an off-the-shelf allogeneic CD19 chimeric antigen receptor natural killer cell therapy (CAR-NK). This CD19 t-haNK (CAR-NK) is a targeted high-affinity natural killer (NK) cell therapy engineered to express a CD19-specifc chimeric antigen re
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Why ImmunityBio Stock Is Skyrocketing Again Today [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? [Yahoo! Finance]Yahoo! Finance
- Ford & BYD reportedly in talks to partner, PNC rises on earnings [Yahoo! Finance Canada]Yahoo! Finance Canada
- ImmunityBio Says Potential Lymphoma Therapy Extends Complete Response to 15 Months [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 1/16/26 - Form 144
- 1/15/26 - Form 8-K
- 1/14/26 - Form 8-K
- IBRX's page on the SEC website